Fractyl Health (GUTS) Non Operating Income (2023 - 2026)
Fractyl Health's (GUTS) quarterly Non Operating Income came in at $30.0 million in Q1 2026, up 2833.4% YoY from $1.0 million in Q1 2025, and up 246.94% on a QoQ basis from -$20.4 million in Q4 2025.
Fractyl Health (GUTS) Non Operating Income (2023 - 2026) Analysis & Trends
Fractyl Health (GUTS) has 4 years of Non Operating Income data on file, last reported at $30.0 million in Q1 2026.
- Quarterly Non Operating Income rose 2833.4% year-over-year to $30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.1 million (down 297.93% YoY) and the FY2025 annual result came in at -$44.1 million, down 277.71% from the prior year.
- Non Operating Income improved to $30.0 million in Q1 2026, from -$20.4 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $30.0 million in Q1 2026 to a low of -$22.9 million in Q3 2025.
- A 4-year average of -$1.2 million and a median of $175000.0 in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income surged 10311.43% — and 2025, when it sank 8617.92%.
- Tracing GUTS's Non Operating Income over 4 years: stood at -$6.2 million in 2023, then surged by 103.87% to $240000.0 in 2024, then slumped by 8617.92% to -$20.4 million in 2025, then jumped by 246.94% to $30.0 million in 2026.
- The last three Non Operating Income figures came in at $30.0 million (Q1 2026), -$20.4 million (Q4 2025), and -$22.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Fractyl Health | 123.81 Mn | 123.81 Mn | - | -6.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.44 Mn |
| Mar 31, 2026 | 30.04 Mn |
| Dec 31, 2025 | -20.44 Mn |
| Sep 30, 2025 | -22.91 Mn |
| Jun 30, 2025 | -1.81 Mn |
| Mar 31, 2025 | 1.02 Mn |
| Dec 31, 2024 | 240,000.00 |
| Sep 30, 2024 | 621,000.00 |
| Jun 30, 2024 | 5.76 Mn |
| Mar 31, 2024 | 18.22 Mn |
| Dec 31, 2023 | -6.20 Mn |
| Sep 30, 2023 | -1.87 Mn |
| Jun 30, 2023 | -18.36 Mn |
| Mar 31, 2023 | 175,000.00 |